U.S. flag An official website of the United States government
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. Compliance Policy for Limited Modifications to Certain Marketed Tobacco Products
  1. Search for FDA Guidance Documents


Compliance Policy for Limited Modifications to Certain Marketed Tobacco Products Guidance for Industry November 2019

Docket Number:
Issued by:
Guidance Issuing Office
Center for Tobacco Products

In this guidance, FDA sets out its compliance policy for premarket review requirements for two types of limited modifications to new tobacco products that were on the market as of August 8, 2016: (1) modifications to battery-operated tobacco products solely to comply with UL 8139; and (2) modifications to liquid nicotine products solely to comply with the Child Nicotine Poisoning Prevention Act of 2015 (CNPPA) flow restrictor requirements for liquid nicotine containers.  This compliance policy provides that FDA does not intend to enforce violations of the premarket review requirements against such modified products on the basis of the modifications described in this guidance. In light of their potential safety risks, FDA strongly encourages manufacturers to remove the currently marketed unmodified tobacco products from the market prior to introducing the modified tobacco products to the market.      

FDA’s guidance documents, including this guidance, do not establish legally enforceable responsibilities.  Instead, guidances describe FDA’s current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited.  The use of the word should in FDA’s guidances means that something is suggested or recommended, but not required.

Submit Comments

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-2019-D-5324.


Back to Top